Menu
Oncoguard Liver logo
exs-Liver-Heroes-13

Promoting surveillance adherence

Empower patients with our customizable patient engagement program

Support that drives adherence

The Oncoguard® Liver Patient Engagement Program helps empower patients to actively manage their health and stay on top of their scheduled HCC testing.

exs-lvr-icon-scheduled-hcc-testing

It is estimated that three million patients in the US qualify for HCC surveillance.1 However, overall surveillance utilization is estimated to be less than 30%2

 

73.7%

Surveillance rates are highest in patients receiving sub-specialty care from gastroenterology/hepatology clinics; 73.7% (66.6-80.3)2

29.5%

In center-based studies that included primary care surveillance, utilization occurred in 29.5% (21.1-38.6%)2

exs-lvr-Patient-Icon

Patients report that issues making it more difficult to complete surveillance include:3

  • Difficulties with scheduling
  • Costs associated with surveillance testing
  • Transportation concerns
exs-lvr-Doctor-Icon

Providers report that barriers to greater utilization of HCC surveillance include:4

  • Lack of information about benefits
  • Limited time available to spend with patients
  • Competing clinical concerns
  • Under-recognition of cirrhosis or liver disease
AdobeStock_392859887-resize

The Oncoguard® Liver solution offers a Patient Engagement Program

Patient engagement and outreach programs have been shown to increase patient adherence to HCC surveillance.5,6,7 Tested interventions such as EMR reminders and mailed outreach have demonstrated to increase relative surveillance utilization by 60%-80%.2

Our tailored Patient Engagement Program was designed to help support patients adhere to routine HCC testing through:

 


exs-lvr-Icon-Brochure

A welcome brochure available for providers to hand out in their office

exs-lvr-icon-testing-education-mailed

Testing education mailed to patients following negative Oncoguard® Liver  test results

exs-lvr-Icon-Calendar

Outreach to remind patients of the importance of ongoing testing 6 months after a negative Oncoguard® Liver test result

The Oncoguard® Liver solution. Exactly what’s needed today.

Find out why Exact Sciences is on a collective journey to detect HCC earlier.

Learn More

References: 1. Beste LA, Ioannou GN, Yang Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol. 2015;13(1):172-179. doi:10.1016/j.cgh.2014.04.033 2. Wolf E, Rich NE, Marrero JA, et al. Utilization of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology. Published online May 8, 2020; 10.1002/hep.31309. doi:10.1002/hep.31309 3. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology. 2017;65(3):875-884. doi:10.1002/hep.28770 4. Simmons OL, Feng Y, Parikh ND, et al. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol. 2019;17(4):766-773. doi:10.1016/j.cgh.2018.07.029 5. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-2921. doi:10.1158/0008-5472.CAN-14-0155 6. Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol. 2019;11(1):1-18. doi:10.4254/wjh.v11.i1.1 7. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2019;17(4):748-755.e3. doi:10.1016/j.cgh.2018.05.057